These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 16649344

  • 1. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA, Heizer KE.
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [Abstract] [Full Text] [Related]

  • 2. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 4. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL, Chu SH, Chiang YJ, Wu CT, Chen Y.
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus in renal transplantation.
    Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [Abstract] [Full Text] [Related]

  • 7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 8. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD.
    J Nephrol; 2004 Jul 15; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC, Warshaw BL.
    Pediatr Transplant; 2005 Aug 15; 9(4):520-2. PubMed ID: 16048606
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus for solid organ transplantation in children.
    Gupta P, Kaufman S, Fishbein TM.
    Pediatr Transplant; 2005 Jun 15; 9(3):269-76. PubMed ID: 15910380
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus: new preparation. No tangible advance in renal transplantation.
    Prescrire Int; 2002 Dec 15; 11(62):165-6. PubMed ID: 12469693
    [Abstract] [Full Text] [Related]

  • 13. [Immunosuppression with sirolimus so donor kidneys survive longer].
    MMW Fortschr Med; 2004 Aug 05; 146(31-32):46-7. PubMed ID: 15529711
    [No Abstract] [Full Text] [Related]

  • 14. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar 05; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 05; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 16. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 05; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 17. Update on transplant pharmacology: sirolimus.
    Hoffmann RL, Roesch T.
    Dimens Crit Care Nurs; 2004 Dec 05; 23(2):69-75. PubMed ID: 15192367
    [Abstract] [Full Text] [Related]

  • 18. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD, Bittencourt VB, Alves AB, Garcia VD, Tumelero A, Antonello JS, Malheiros D.
    Transplant Proc; 2006 Dec 05; 38(6):1901-3. PubMed ID: 16908317
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P, Ruggenenti P, Remuzzi G.
    Lancet; 2009 Apr 11; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract] [Full Text] [Related]

  • 20. Current approaches to the use of sirolimus in renal transplantation.
    Kahan BD.
    Transplant Proc; 2009 Oct 11; 41(8):3011-5. PubMed ID: 19857664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.